Viracta Therapeutics, Inc.: insider trades · United States · SEC (Form 4)

About Viracta Therapeutics, Inc.

Viracta Therapeutics, Inc. is a U.S.-listed biotechnology company traded on the NASDAQ market in the United States, historically based in San Diego, California. The company was incorporated in Delaware in February 1998 and later took its current form through a merger with Sunesis Pharmaceuticals, which shaped it into a clinical-stage oncology platform focused on highly specialized, hard-to-treat cancers. Viracta’s strategic positioning has centered on precision oncology with a particular emphasis on virus-associated malignancies, especially Epstein-Barr virus (EBV)-driven cancers. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1061027/000119312524118083/d770324dars.pdf?utm_source=openai)) Viracta’s lead asset was Nana-val, an all-oral investigational combination of nanatinostat, an HDAC inhibitor, and valganciclovir, an antiviral agent. The core development program was NAVAL-1, a multinational Phase 2 basket study evaluating the therapy across multiple relapsed or refractory EBV-positive lymphoma subtypes, with additional work in EBV-positive solid tumors. From a market-position perspective, Viracta stood out through a differentiated biological hypothesis and a niche target population, but it also faced the classic constraints of small-cap biotech: a narrow addressable market, high clinical development risk, and continued dependence on external financing. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1061027/000119312524118083/d770324dars.pdf?utm_source=openai)) Recent corporate developments materially changed the investment case. In July 2024, Viracta announced a workforce reduction of about 23% as part of a cost-containment effort. In November 2024, management said cash, cash equivalents and short-term investments totaled about $21.1 million and that resources were being reprioritized toward the second-line EBV-positive PTCL segment. Then, on February 5, 2025, the company announced plans to wind down operations after its board approved employee terminations effective February 3, 2025. Viracta’s current website now states that the company is no longer operating, while directing users to prior SEC filings. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1061027/000095017024087020/virx-20240722.htm?utm_source=openai)) For French-speaking investors in France, Belgium, and Switzerland, Viracta is therefore best viewed as a highly speculative biotech case in liquidation rather than a conventional growth story. The company’s history nevertheless reflects a clear scientific thesis in viral oncology and precision medicine, built around a differentiated mechanism and a focused hematology-oncology pipeline. The challenge was always commercialization at scale: promising biology is not enough when a company remains dependent on a single late-stage program and on capital markets to fund execution. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1061027/000119312524118083/d770324dars.pdf?utm_source=openai))